Hypoxia-inducible factors enhance glutamate signaling in cancer cells
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
// Hongxia Hu 1,2,3 , Naoharu Takano 2,3 , Lisha Xiang 2,3,4 , Daniele M. Gilkes 2,3 , Weibo Luo 2,3,5 , and Gregg L. Semenza 2,3,5,6 1 Predoctoral Training Program in Human Genetics, Johns Hopkins University School of Medicine, Baltimore, MD 2 McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 3 Vascular Program, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 4 Department of Oncology and Southwest Cancer Center, Southwest Hospital, Third Military Medical University, Chongqing, China 5 Department of Biological Chemistry, Johns Hopkins University School of Medicine, Baltimore, MD 6 Departments of Medicine, Oncology, Pediatrics, Radiation Oncology, Johns Hopkins University School of Medicine, Baltimore, MD Correspondence: Gregg L. Semenza, email: // Keywords :AMPA receptor, clear cell renal carcinoma, hepatocellular carcinoma, HIF-1 Received : October 01, 2014 Accepted : October 15, 2014 Published : October 15, 2014 Abstract Signaling through glutamate receptors has been reported in human cancers, but the molecular mechanisms are not fully delineated. We report that in hepatocellular carcinoma and clear cell renal carcinoma cells, increased activity of hypoxia-inducible factors (HIFs) due to hypoxia or VHL loss-of-function, respectively, augmented release of glutamate, which was mediated by HIF-dependent expression of the SLC1A1 and SLC1A3 genes encoding glutamate transporters. In addition, HIFs coordinately regulated expression of the GRIA2 and GRIA3 genes, which encode glutamate receptors. Binding of glutamate to its receptors activated SRC family kinases and downstream pathways, which stimulated cancer cell proliferation, apoptosis resistance, migration and invasion in different cancer cell lines. Thus, coordinate regulation of glutamate transporters and receptors by HIFs was sufficient to activate key signal transduction pathways that promote cancer progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hypoxia-inducible factors in physiology and medicine
Semenza, G. L. (2012) · Cell · doi:10.1016/j.cell.2012.01.021 · Cited by 3,645
Self-citationGlutamate Receptor Ion Channels: Structure, Regulation, and Function
Traynelis, S. F., Wollmuth, L. P., McBain, C. J., Menniti, F. S., Vance, K. M., Ogden, K. K., Hansen, K. B., Yuan, H., Myers, S. J., & Dingledine, R. (2010) · Pharmacological Reviews · doi:10.1124/pr.109.002451 · Cited by 3,568 · cited 1×
“AMPA receptors are responsible for the vast majority of fast excitatory synaptic transmission within the mammalian central nervous system [38].”
Comprehensive molecular characterization of clear cell renal cell carcinoma
The Cancer Genome Atlas Research Network (2013) · Nature · doi:10.1038/nature12222 · Cited by 3,485 · cited 1×
“The most notable example of a genetic alteration driving HIF activity is in clear cell Renal Cell Carcinoma (ccRCC), which is characterized by a high incidence of VHL loss-of-function due to either mutation or epigenetic silencing, which leads to high HIF activity even under non-hypoxic conditions (Network, 2013).”
Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway.
Kaelin, W. G., & Ratcliffe, P. J. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.04.009 · Cited by 3,251 · cited 2×
“Proline residues Pro402 and Pro564 of human HIF-1α (Pro405 and Pro531 of HIF-2α) are subjected to O2 dependent hydroxylation by prolyl hydroxylase domain proteins (PHDs) [2-4].”
Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics
Semenza, G. L. (2010) · Oncogene · doi:10.1038/onc.2009.441 · Cited by 1,712 · cited 2×
“10 metastasis, treatment failure, and patient mortality in many types of cancer (Semenza, 2003; Semenza, 2010a).”
Self-citationHIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression
Keith, B., Johnson, R. S., & Simon, M. C. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3183 · Cited by 1,693 · cited 1×
“5 Specific proline (P) residues in the HIF-1α or HIF-2α O2-dependent degradation domain (ODDD) are subjected to O2 dependent hydroxylation by prolyl-4-hydroxylase domain proteins (PHDs) (Kaelin and Ratcliffe, 2008; Keith et al., 2012; Prabhakar and Semenza, 2012).”
Zhang, H., Gao, P., Fukuda, R., Kumar, G., Krishnamachary, B., Zeller, K. I., Dang, C. V., & Semenza, G. L. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.04.001 · Cited by 885
Self-citationThe Role of Hypoxia in Development of the Mammalian Embryo
Dunwoodie, S. L. (2009) · Developmental Cell · doi:10.1016/j.devcel.2009.11.008 · Cited by 651 · cited 1×
“HIFs have been implicated in many developmental, physiological and pathophysiological processes [3, 5, 6].”
Prabhakar, N. R., & Semenza, G. L. (2012) · Physiological Reviews · doi:10.1152/physrev.00030.2011 · Cited by 641
Digoxin and other cardiac glycosides inhibit HIF-1α synthesis and block tumor growth
Zhang, H., Qian, D. Z., Tan, Y. S., Lee, K., Gao, P., Ren, Y. R., Rey, S., Hammers, H., Chang, D., Pili, R., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809763105 · Cited by 624 · cited 1×
“Previously studies have demonstrated that administration of the HIF-1 inhibitor digoxin also significantly inhibits Hep3B tumor xenograft growth (Zhang et al., 2008) and HIF inhibitor also impairs ccRCC tumor growth (Chintala et al.”
Self-citationTimmerman, L. A., Holton, T., Yuneva, M., Louie, R. J., Padró, M., Daemen, A., Hu, M., Chan, D. A., Ethier, S. P., van ‘t Veer, L. J., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.08.020 · Cited by 573
HIF-α effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma
Gordan, J. D., Lal, P., Dondeti, V. R., Letrero, R., Parekh, K. N., Oquendo, C. E., Greenberg, R. A., Flaherty, K. T., Rathmell, W. K., Keith, B., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.10.016 · Cited by 493 · cited 3×
“Because one-third of ccRCC tumors with VHL lossof-function exclusively overexpress HIF-2α (“H2”) and two-thirds overexpress both HIF-1α and HIF-2α (“H1H2”) [44], we analyzed two VHL mutant ccRCC cell lines, 786O and RCC4, which represent the H2 and H1H2 subtypes, respectively.”
InfluentialBeyond the role of glutamate as a neurotransmitter
Nedergaard, M., Takano, T., & Hansen, A. J. (2002) · Nature Reviews Neuroscience · doi:10.1038/nrn916 · Cited by 450 · cited 1×
“However, glutamate signaling has been implicated in various non-excitable tissues, as well as in several diseases including cancer [11].”
The x cystine/glutamate antiporter: A potential target for therapy of cancer and other diseases
Lo, M., Wang, Y., & Gout, P. W. (2008) · Journal of Cellular Physiology · doi:10.1002/jcp.21366 · Cited by 399 · cited 1×
“Over 50% of glutamate release by glioma cell lines was attributed to the xc - cystine/glutamate antiporter, which has been implicated in other cancer cells that release glutamate [45, 47].”
Development of HIF‐1 inhibitors for cancer therapy
Onnis, B., Rapisarda, A., & Melillo, G. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00876.x · Cited by 268
Xiang, L., Gilkes, D. M., Chaturvedi, P., Luo, W., Hu, H., Takano, N., Liang, H., & Semenza, G. L. (2014) · Journal of Molecular Medicine · doi:10.1007/s00109-013-1102-5 · Cited by 114 · cited 3×
“The Ki67 staining was quantified using ImageJ software (NIH) [64].”
InfluentialSelf-citation
Cited by
Gide, T. N., Quek, C., Menzies, A. M., Tasker, A. T., Shang, P., Holst, J., Madore, J., Lim, S. Y., Velickovic, R., Wongchenko, M., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.01.003 · Cited by 1,047
Bhutia, Y. D., Babu, E., Ramachandran, S., & Ganapathy, V. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3745 · Cited by 481
Amino acid transporter LAT1 (SLC7A5) as a molecular target for cancer diagnosis and therapeutics
Kanai, Y. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107964 · Cited by 283
Hypoxia-Inducible Factors and Cancer
Jun, J. C., Rathore, A., Younas, H., Gilkes, D., & Polotsky, V. Y. (2017) · Current Sleep Medicine Reports · doi:10.1007/s40675-017-0062-7 · Cited by 248
Self-citationXiang, L., Mou, J., Shao, B., Wei, Y., Liang, H., Takano, N., Semenza, G. L., & Xie, G. (2019) · Cell Death & Disease · doi:10.1038/s41419-018-1291-5 · Cited by 223
Self-citation
Metadata
- Authors
- Hu, H., Takano, N., Xiang, L., Gilkes, D. M., Luo, W., & Semenza, G. L.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2014-10-15
- Volume
- 5
- Issue
- 19
- Pages
- 8853-8868
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2095882387
- Cited by
- 75
- References
- 16
- FWCI
- 1.85
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.